Only certain healthy, older people could stave off cancer using low-dose aspirin (LDA), according to a secondary analysis of a large clinical trial that flags those who might benefit.

Primary results from the trial did not show that 100 mg per day enteric-coated aspirin prevented cancer over the course of five years among its nearly 20,000 participants.

But the extended analysis, published in JAMA Oncology , suggests there were benefits for older people and those who were non-smokers, had a family history of cancer, or a lower body mass index.

Others who benefited included participants with the age-related phenomenon of clonal hematopoiesis of indeterminate potential (CHIP) at a variant allele frequency (VAF) of at least 10%.

The researchers demonstrate a connection with CHIP and t

See Full Page